Although a generally accepted definition of ''elderly'' still does not exist, in a medical context, persons over the age of 65 are often considered to be elderly. As life expectancy rates have increased within the last decades and continuously increase every year by approximately 3 months [1], this segment of the population has increased, particularly in Western countries. Because cancer is a disease of aging, the risk of developing malignant disease including head and neck cancer is highest in this patient population. It also follows that malignancy-related mortality is highest among the elderly.Younger patients with head and neck cancers have a much better overall prognosis. A comparative survival analysis revealed that patients with head and neck cancer who are aged 40 years or younger at the time of diagnosis show significantly improved 5-year survival when compared to older patients [2]. For all age groups the 5-year survival rate of patients with a newly diagnosed head and neck cancer is approximately 60 % at diagnosis. However, prognosis is a dynamic process that improves after the initial critical years of recurrence-free survival. Conditional relative survival shows clinically relevant variations according to time since diagnosis, type of cancer, and age [3]. Conditional survival rates can better analyze and reflect actual life expectancy. After 3 years of survival, the conditional survival rate improves from 60 % up to 80 %. However, long-term survival rates stagnate at 80 %. Patients cured of and neck cancer face an excess mortality of about 20 % in long-term follow-up [4]. The critical reason for this is attributed to the comorbid burden of head and neck cancer patients, connected with unhealthy habits and general lifestyle choices.Comorbidities in cancer patients are defined as one or more unrelated diseases present at the time of cancer diagnosis. Particularly in elderly patients, these predominantly consist of reduced organ and cognitive functions, malnutrition, polypharmacy, and socio-economic factors. Most studies show that approximately 60 % of head and neck cancer patients have concurrent illnesses [5]. For better evaluation of comorbidities, weighted assessment systems like Adult Comorbidity Evaluation-27 (ACE-27), and Charlson Comorbidity Index (CCI) include the occurrence of comorbidities as well as their degrees. Comorbidities exist in 46 % of head and neck cancer